top of page

Alzinova Collaborates With Captario To Optimize Clinical Development

Alzinova AB, a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s disease, has recently initiated a collaboration with Captario to further optimize Alzinova's development strategies.

Alzinova is currently preparing for an upcoming Phase 1b clinical study with its therapeutic vaccine, ALZ-101 for the treatment of Alzheimer’s disease. The Gothenburg-based company is using the artificial intelligence (AI)-driven modeling and simulation capabilities of Captario SUM™ to facilitate decision making and optimize strategic development processes.

Kristina Torfgård, CEO of Alzinova, says, “Captario's ability to model strategic options and compare them in real-time is very powerful. The tool has helped us to generate exciting new opportunities and ideas about how we can optimize our development program and make ALZ-101 even more attractive to potential partners.”

Johannes Vänngård, CEO Captario, says, "It is a great honor to be able to support Alzinova in their important mission to develop a therapy that helps patients with Alzheimer's disease. There is much to be learned from working with highly innovative and leading-edge biopharma companies like Alzinova. Our collaboration demonstrates that Captario's offering provides value not only to large pharma companies but also to smaller innovation-focused companies in the life science industry.”

For more information, please contact:

About Alzinova

Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further.


bottom of page